Scarica l'app Stockscreener
3.76
1.62%
0.06
Marker Therapeutics Inc Borsa (MRKR) Ultime notizie
US Penny Stocks To Consider In October 2024 - Simply Wall St
Allogeneic Hematopoietic Stem Cell Transplant Market to - GlobeNewswire
Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - India Shorts
Kids Marker Market to hit USD 257.4 million by 2032, says Global Market Insights Inc. - Yahoo Finance
PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - PR Newswire UK
AML cell therapy trials to watch in 2024 targeting GvHD - Yahoo Finance
Markforged (NYSE:MKFG) Sees Unusually-High Trading Volume - Defense World
Top 3 Health Care Stocks That May Explode This Month - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines
On Tuesday’s show: Medical 'Blind Spots' - WJCT NEWS
ProShare Advisors LLC Has $47.68 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - PR Newswire
ProShare Advisors LLC Sells 43,073 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Meiji Yasuda Asset Management Co Ltd. Has $580,000 Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Washington Journal: Dr. Marty Makary Discusses His Book "Blind Spots" & Health Care in the U.S. - C-SPAN
Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch
Hematopoietic Stem Cell Transplantation Global Market Report 2024 Size and Forecast - WhaTech
Edgestream Partners L.P. Invests $1.67 Million in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Moderna Inc [NASDAQ: MRNA] Sees Decrease in Stock Value - Knox Daily
Hematopoietic stem cell transplantation (HSCT) Market to See - openPR
Down 13% in 1 Day, Is Moderna Stock in Trouble? - The Motley Fool
Quest Partners LLC Trims Stock Position in Marsh & McLennan Companies, Inc. (NYSE:MMC) - MarketBeat
Moderna Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Parallel Advisors LLC Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
Dr. Marty Makary Talks "Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health" - The Clay Travis & Buck Sexton Show
Acadian Asset Management LLC Purchases New Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Dai ichi Life Insurance Company Ltd Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Wedbush Securities Inc. Invests $393,000 in First Trust NASDAQ BuyWrite Income ETF (NASDAQ:FTQI) - Defense World
Biodesix, Inc. (NASDAQ:BDSX) Receives Average Recommendation of “Buy” from Analysts - Defense World
United Parks & Resorts Inc. (NYSE:PRKS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
Palisade Bio Reports Data Demonstrating PDE4B Expression in - GlobeNewswire
Short Interest in Solventum Co. (NYSE:SOLV) Drops By 17.8% - Defense World
VanEck Pharmaceutical ETF (NASDAQ:PPH) Short Interest Down 17.3% in August - Defense World
MYR Group Inc. (NASDAQ:MYRG) Short Interest Update - Defense World
Phillips 66 (NYSE:PSX) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
Bank of New York Mellon Corp Acquires 36,810 Shares of SEI Investments (NASDAQ:SEIC) - Defense World
Anthem Blue Cross and Blue Shield unveils a new historic marker in Columbus - Yahoo Finance
Raymond James & Associates Has $10.59 Million Stock Holdings in InvescoBulletShares2033 Corporate Bond ETF (NASDAQ:BSCX) - Defense World
MRKR Stock Earnings: Marker Therapeutics Beats EPS for Q2 2024 - MSN
Will APOLLO Study Of MT-601 In Lymphoma Make A Mark? - RTTNews
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study - MSN
Marker Therapeutics Awarded $2 Million Grant from NIH in - GlobeNewswire
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma - StockTitan
Breast Tissue Markers Market Size to be Worth USD 5.8 billion by 2034, Growing at CAGR of 8.3% | Exclusive Report by Transparency Market Research, Inc. - Yahoo Finance
NightHawk Changes Name To Scorpius Holdings - Contract Pharma
IDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
(MRKR) Investment Report - Stock Traders Daily
Soligenix (NASDAQ:SNGX) & Marker Therapeutics (NASDAQ:MRKR) Head-To-Head Contrast - Defense World
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $40.60 - Defense World
Financial Survey: EPR Properties (NYSE:EPR) and Bimini Capital Management (OTCMKTS:BMNM) - Defense World
Head to Head Comparison: Skye Bioscience (NASDAQ:SKYE) and Merck KGaA (OTCMKTS:MKGAF) - Defense World
Hematopoietic stem cell transplantation (HSCT) Market - openPR
Neural and behavioral markers of inhibitory control predict symptom improvement during internet-delivered cognitive behavioral therapy for depression | Translational Psychiatry - Nature.com
Strong week for Marker Therapeutics (NASDAQ:MRKR) shareholders doesn't alleviate pain of five-year loss - Simply Wall St
Marker Therapeutics (NASDAQ:MRKR) Stock Price Up 5% - MarketBeat
Marker Therapeutics (NASDAQ:MRKR) Trading Up 5% - Defense World
Pliant Therapeutics Inc. (PLRX) Reports Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial - StreetInsider.com
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures - BioSpace
(MRKR) Trading Report - Stock Traders Daily
BioZorb Lawuit- Breast Biopsy Marker Recall Lawyer - Levin Papantonio
MRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023 - InvestorPlace
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors - Quantisnow
2.45%
2.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):